KALA BIO, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by KALA BIO, Inc. (Nasdaq: KALA) on February 20, 2026, reporting an event that occurred on February 16, 2026. The company is incorporated in Delaware and operates as a biopharmaceutical entity.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On February 16, 2026, David Lazar resigned as a member of the Board of Directors, effective immediately. The company stated that Mr. Lazar's resignation was not related to any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- David Lazar resigned from the Board of Directors effective February 16, 2026.
- The resignation was not caused by any disagreement with the company.
- Avi Minkowitz, Chief Executive Officer, signed the report on February 20, 2026.
- No financial data or operational updates were included in this specific filing.